PROPHARMA
ActiveSummary
PROPHARMA has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €250,000 and a net result of €84,153. Equity is growing by about 3.9% per year across the filed financial years. Its solvency ranks better than 40% of 4,921 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
27-05
NBB filing
Annual accounts filed
financial year 2025 · full format
2025
16-07
NBB filing
Annual accounts filed
financial year 2024 · full format
2024
29-08
NBB filing
Annual accounts filed
financial year 2023 · full format · 29 days late
2023
31-12
Financial
Highest result from 2018 to 2025net €144,124 ▲80.2%
Operating result €193,856, net result €144,124, both a record.
31-12
Financial
Equity above €500,000equity €529,326 ▲10.4%
3 profitable years in a row build equity to €529,326.
20-06
NBB filing
Annual accounts filed
financial year 2022 · full format
2022
17-08
NBB filing
Annual accounts filed
financial year 2021 · full format · 17 days late
2021
31-12
Financial
Back to profitnet €94,595
Net result €94,595 after one loss-making year.
17-08
NBB filing
Annual accounts filed
financial year 2020 · full format · 17 days late
2020
31-12
Financial
Weakest financial yearnet -€37,964
Net result drops to -€37,964, the lowest in the series; recovery starts the following year.
03-09
NBB filing
Annual accounts filed
financial year 2019 · full format · 34 days late
2019
31-07
NBB filing
Annual accounts filed
financial year 2018 · full format
2018
16-07
NBB filing
Annual accounts filed
financial year 2017 · full format
2017
02-08
NBB filing
Annual accounts filed
financial year 2016 · full format · 2 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.